Michael R. Yeaman
University of California, Los Angeles
223 Papers
1.2K Citations
Michael R. Yeaman is an academic researcher from University of California, Los Angeles. The author has contributed to research in topics: Staphylococcus aureus & Biology. The author has an hindex of 67, co-authored 197 publications. Previous affiliations of Michael R. Yeaman include University of Michigan & Los Angeles Biomedical Research Institute.
Chat about Author
Papers
Mechanisms of Antimicrobial Peptide Action and Resistance
TL;DR: The intention of this review is to illustrate the contemporary structural and functional themes among mechanisms of antimicrobial peptide action and resistance.
3K
Als3 Is a Candida albicans Invasin That Binds to Cadherins and Induces Endocytosis by Host Cells
Quynh T. Phan,Carter L. Myers,Yue Fu,Yue Fu,Donald C. Sheppard,Michael R. Yeaman,Michael R. Yeaman,William Welch,Ashraf S. Ibrahim,Ashraf S. Ibrahim,John E. Edwards,John E. Edwards,Scott G. Filler,Scott G. Filler +13 more
TL;DR: Als3 is a fungal invasin that mimics host cell cadherins and induces endocytosis by binding to N-cadherin on endothelial cells and E-cadaverin on oral epithelial cells.
Antimicrobial Peptides from Human Platelets
TL;DR: Findings suggest a direct antimicrobial role for platelets as they are activated to release peptides in response to trauma or mediators of inflammation.
596
Multidimensional signatures in antimicrobial peptides
TL;DR: The multidimensional signature model provides a unifying structural theme in broad classes of antimicrobial peptides, will facilitate discovery of antimacterial peptides as yet unknown, and offers insights into the evolution of molecular determinants in these and related host defense effector molecules.
402
Persistent bacteremia due to methicillin-resistant Staphylococcus aureus infection is associated with agr dysfunction and low-level in vitro resistance to thrombin-induced platelet microbicidal protein.
Vance G. Fowler,George Sakoulas,Lauren M. McIntyre,Lauren M. McIntyre,Venkata G. Meka,Robert D. Arbeit,Christopher H. Cabell,Martin E. Stryjewski,George M. Eliopoulos,L. Barth Reller,G. Ralph Corey,Tiffanny Jones,Natalie Lucindo,Michael R. Yeaman,Michael R. Yeaman,Arnold S. Bayer,Arnold S. Bayer +16 more
TL;DR: Isolates from patients with PB differed from those in patients with RB, in several in vitro characteristics, and it will be necessary to define how these factors might affect clinical outcome.
362